Literature DB >> 22735605

How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.

Mariana V Machado1, João Coutinho, Fátima Carepa, Adília Costa, Helena Proença, Helena Cortez-Pinto.   

Abstract

BACKGROUND: Adipose tissue contributes to nonalcoholic fatty liver disease (NAFLD), being a source of fatty acids and cytokines such as leptin and adiponectin, and regulating ghrelin production. Their role in NAFLD pathogenesis remains controversial. We aimed to study the influence of those cytokines on the severity of NAFLD.
METHODS: Morbidly obese individuals with biopsy-proven NAFLD were recruited. The NAFLD activity score was applied to liver histology. Serum concentrations of adiponectin, leptin, and ghrelin were determined.
RESULTS: Eighty-two patients were included, 13% with nonalcoholic steatohepatitis (NASH). Hypertriglyceridemia (P=0.018) and metabolic syndrome (P=0.040) were independent factors associated with NASH. Leptin associated positively and ghrelin associated negatively with BMI; adiponectin associated negatively with the waist to hip ratio. Adiponectin associated negatively with insulin resistance, hypertension, and metabolic syndrome; ghrelin associated positively with diabetes mellitus. Adiponectin below 23 ng/ml associated with NASH (odds ratio 12.95, P<0.001). Leptin increased progressively (P=0.032) and adiponectin decreased (P=0.004) with increasing severity of steatosis. Also, leptin increased progressively with more severe fibrosis (P=0.053). A formula incorporating the three cytokines yielded an AUROC of 0.789 (P=0.002), a sensitivity of 81.8%, and a specificity of 76.1% for NASH.
CONCLUSION: An imbalance in adiponectin, leptin, and ghrelin seems to be associated with more severe NAFLD. A formula combining the three cytokines showed good accuracy for NASH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22735605     DOI: 10.1097/MEG.0b013e32835609b0

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  37 in total

Review 1.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

2.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.

Authors:  Jamie E Mells; Ping P Fu; Pradeep Kumar; Tekla Smith; Saul J Karpen; Frank A Anania
Journal:  J Nutr Biochem       Date:  2014-12-06       Impact factor: 6.048

3.  Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.

Authors:  Varun Chandrashekaran; Suvarthi Das; Ratanesh Kumar Seth; Diptadip Dattaroy; Firas Alhasson; Gregory Michelotti; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Biochim Biophys Acta       Date:  2015-10-22

Review 4.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

Review 5.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 6.  Obesity, fatty liver disease and intestinal microbiota.

Authors:  Nur Arslan
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 7.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

Review 8.  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Stergios A Polyzos; Konstantinos N Aronis; Jannis Kountouras; Dimitrios D Raptis; Maria F Vasiloglou; Christos S Mantzoros
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

Review 9.  The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD.

Authors:  Maya Balakrishnan; Rohit Loomba
Journal:  J Clin Gastroenterol       Date:  2020-02       Impact factor: 3.062

10.  Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet?

Authors:  Ahilan Arulanandan; Rohit Loomba
Journal:  Curr Hepatol Rep       Date:  2015-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.